Herpes zoster vaccine is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles). According to GlobalData, Phase I drugs for Herpes Zoster (Shingles) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Herpes zoster vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Herpes zoster vaccine overview

Vaccine is under development for the prevention of herpes zoster infections. It is administered by intramuscular route.

Beijing Luzhu Biotechnology overview

Beijing Luzhu Biotechnology, a subsidiary of Chongqing Zhifei Biological Products Co Ltd, is a biotechnology company focused on manufacture and development of human vaccines and therapeutic biologics to develop multiple polysaccharide-protein conjugate vaccines, polysaccharide vaccines and virus inactivated vaccines. The company is headquartered in Beijing City, Beijing, China.

For a complete picture of Herpes zoster vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.